Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer

Background: Programmed cell death protein 1(PD-1) blockade has become a standard second-line treatment option for patients with advanced non-small cell lung cancer (NSCLC) without a driver gene mutation. Previous clinical studies showed that the objective response rate (ORR) of PD-1 blockade as seco...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lingdi, Ma, Baozhen, Yang, Yonghao, Li, Tiepeng, Han, Lu, Gao, Quanli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186846/
https://www.ncbi.nlm.nih.gov/pubmed/32373522
http://dx.doi.org/10.3389/fonc.2020.00507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186846/
https://www.ncbi.nlm.nih.gov/pubmed/32373522
http://dx.doi.org/10.3389/fonc.2020.00507

Ejemplares similares